Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — European Society for Medical Oncology (ESMO) Meeting 2026
8 slides from Zymeworks's conference presentation, October 2026
Slide 1: Randomized dose optimization of ZW191 in heavily pretreated platinum-resistant ovarian cancer (PROC)
LBA40 Randomized dose optimization of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) Jung-Yun Lee,1 David Sommerhalder,2 Jose Alejandro Pérez-Fidalgo,3 Daniel S.W. Tan,4 Kosei Hasegawa,5 Patricia LoRusso,6 Kenichi Harano,7 David M. O’Malley,8 Sarah E. Church,9 Lin
Slide 2: Disclosure information
Disclosure information Jung-Yun Lee, MD, PhD I have the following relevant financial relationships to disclose: Personal financial relationships • Honoraria – Abbvie, AstraZeneca, Daiichi Sankyo, Eisai, GSK, MSD, Roche, Takeda • Consulting/Advisory/Steering Committee – Abbvie, AstraZeneca, CanariaBi
Slide 3: Background and study design
Background and study design • Treatment options remain limited for heavily pretreated patients with platinum-resistant ovarian cancer (PROC), PART 1 PART 2 including those with high-grade serous and clear cell KEY ELIGIBILITY CRITERIA DOSE ESCALATIONa,b DOSE OPTIMISATIONb histology1 • ≥18 years of a
Slide 4: Patients were heavily pretreated and had a wide range of FRα expression
Patients were heavily pretreated and had a wide range of FRα expression Demographics and baseline 6.4 mg/kg 9.6 mg/kg Total 6.4 mg/kg 9.6 mg/kg Total Prior therapies characteristics (n=37) (n=43) (N=80) (n=37) (n=43) (N=80) Age, years, median (range) 61 (42-78) 61 (40-79) 61 (40-79) Prior lines of t
Slide 5: cORR was 65% at 6.4 mg/kg and 55% at 9.6 mg/kg in high-grade serous PROC
cORR was 65% at 6.4 mg/kg and 55% at 9.6 mg/kg in high-grade serous PROC High-grade serous Clear cell High-grade serous 6.4 mg/kg 9.6 mg/kg 40 PROC (n=31) (n=38) 30 cORR, % (95% CI) 64.5 (45.4, 80.8) 55.3 (38.3, 71.4) Percentage Change From Baseline in Sum of Diameters 20 DCR, % (95% CI) 100 (88.8,
Slide 6: Responses to ZW191 were deep and durable
Responses to ZW191 were deep and durable mDOR was not reached with 45% of participants continuing treatment ZW191 ZW191 6.4 mg/kg 9.6 mg/kg 6.4 mg/kg 9.6 mg/kg 100 HIGH-GRADE SEROUS High-grade serous 100 High-grade serous Percentage Change From Baseline in Sum of Diameters Percentage Change From Bas
Slide 7: ZW191 was well tolerated
ZW191 was well tolerated TEAEs of any grade occurring in ≥15% of patients 6.4 mg/kg 9.6 mg/kg TEAE, n (%) (n=37) (n=43) ZW191 6.4 mg/kg ZW191 9.6 mg/kg Any TEAE 35 (95) 43 (100) Nausea Neutropenia Grade ≥3 TEAE 20 (54) 32 (74) Anaemia Grade ≥3 TRAE 8 (22) 19 (44) Constipation Serious TEAEs 16 (43) 2
Slide 8: Conclusions
Conclusions ZW191 demonstrated impressive efficacy in heavily pretreated PROC across FRa expression • Impressive efficacy at doses 6.4 and 9.6 mg/kg across FRα expression in HGSOC – cORR was 65% at 6.4 mg/kg and 55% at 9.6 mg/kg – Strong activity was observed in high FRα expression with cORR of 69%
Zymeworks — European Society for Medical Oncology (ESMO) Meeting 2026 on 6ix